Inappropriate ADH Syndrome: Clinical Trials

11 trials for Inappropriate ADH Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 2 terminated. 11 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 9, Terminated 2
Phase 23Completed 3

Follow Inappropriate ADH Syndrome: new trials by email Literature Review of Inappropriate ADH Syndrome trials Research Report on Inappropriate ADH Syndrome

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland172017-12-152021-12-13
A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
Tolvaptan Oral Tablet - Syndrome of Inappropriate Antidiuretic Hormone Secretion
Phase 3CompletedOtsuka Pharmaceutical Co., Ltd.162017-03-022020-11-02
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
Empagliflozin, Placebo - SIADH
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland882016-09-052019-06-13
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome
Phase 2 / Phase 3CompletedUniversity Hospital, Basel, Switzerland152016-03-012016-08-10
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
tolvaptan, Fluid Restriction - Hyponatremia, Dilutional Hyponatremia
Phase 3TerminatedOtsuka Pharmaceutical Development & Commercialization, Inc.1242010-10-012014-10-30
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
Lixivaptan, Placebo - Euvolemic Hyponatremia
Phase 3CompletedCardioKine Inc.2062009-06-012011-06-28
A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
Satavaptan, placebo - Hyponatremia, Inappropriate ADH Syndrome
Phase 3TerminatedSanofi22008-07-012016-05-26
Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
SR121463B - Inappropriate ADH Syndrome, Hyponatremia
Phase 3CompletedSanofi572005-07-012009-01-21
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
SR121463B - Inappropriate ADH Syndrome, Hyponatremia
Phase 3CompletedSanofi772004-05-012008-12-10
Study of Ascending Levels of Tolvaptan in Hyponatremia
Tolvaptan, Placebo - Hyponatremia
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.2432003-11-012026-07-13
"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
tolvaptan, placebo matching tolvaptan - Hyponatremias, Water Intoxication
Phase 3CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.2052003-04-012026-07-13

Narrower conditions

Hyponatremia (9)  ·  Diabetes Insipidus (2)  ·  Fibrosis (2)  ·  Heart Failure (1)  ·  Water Intoxication (1)  ·  Water-Electrolyte Imbalance (1)

Broader conditions

Brain Diseases (11)  ·  Central Nervous System Diseases (11)  ·  Endocrine System Diseases (11)  ·  Hypothalamic Diseases (11)  ·  Metabolic Diseases (11)  ·  Nervous System Diseases (11)  ·  Nutritional and Metabolic Diseases (11)  ·  Pituitary Diseases (11)  ·  Water-Electrolyte Imbalance (10)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Kidney Diseases (2)  ·  Male Urogenital Diseases (2)  ·  Pathologic Processes (2)  ·  Pathological Conditions, Signs and Symptoms (2)

Interventions

Tolvaptan (4)  ·  empagliflozin (3)  ·  satavaptan (3)  ·  Tablets (1)  ·  lixivaptan (1)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (3)  ·  Sanofi (3)  ·  University Hospital, Basel, Switzerland (3)  ·  CardioKine Inc. (1)  ·  Otsuka Pharmaceutical Co., Ltd. (1)

Countries

United States (6)  ·  Switzerland (4)  ·  Belgium (3)  ·  Germany (3)  ·  Brazil (2)  ·  Canada (2)  ·  Hong Kong (2)  ·  Hungary (2)  ·  Australia (1)  ·  Croatia (1)  ·  Czechia (1)  ·  France (1)  ·  India (1)  ·  Israel (1)  ·  Italy (1)

Top investigators

Ann Dandurand, MD (1)  ·  Frank Czerwiec, MD, PhD (1)  ·  Mirjam Christ-Crain, Prof. (1)  ·  Mirjam Christ-Crain, Prof. Dr. MD (1)  ·  Mirjam Christ-Crain, Prof., MD (1)  ·  Nestor Molfino, MD (1)

Results publications

PMID 17105757, PMID 22027579, PMID 25151571, PMID 34412521, PMID 36396331, PMID 37098131, PMID 42522233

NIH funding

2015 (1), 2017 (1)